{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:01:55Z","timestamp":1790913715396,"version":"4.1.0"},"reference-count":23,"publisher":"Scientific Scholar","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background &amp; objectives:<\/jats:title>\n                    <jats:p>Both innovator and generic imatinib are approved for the treatment of Chronic Myeloid Leukaemia-Chronic phase (CML-CP). Currently, there are no studies on the feasibility of treatment-free remission (TFR) with generic imatinib. This study attempted to determine the feasibility and efficacy of TFR in patients on generic Imatinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      In this single-centre prospective Generic Imatinib-Free Trial-in-CML-CP study, twenty six patients on generic imatinib for \u22653 yr and in sustained deep molecular response (BCR ABL\n                      <jats:sup>IS<\/jats:sup>\n                      \u22640.01% for more than two years) were included. After treatment discontinuation, patients were monitored with complete blood count and BCR ABL\n                      <jats:sup>IS<\/jats:sup>\n                      by real-time quantitative PCR monthly for one year and three monthly thereafter. Generic imatinib was restarted at single documented loss of major molecular response (BCR ABL\n                      <jats:sup>IS<\/jats:sup>\n                      &gt;0.1%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At a median follow up of 33 months (interquartile range 18.7-35), 42.3 per cent patients (n=11) continued to be in TFR. Estimated TFR at one year was 44 per cent. All patients restarted on generic imatinib regained major molecular response. On multivariate analysis, attainment of molecularly undetectable leukaemia (&gt;MR5) prior to TFR was predictive of TFR [\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.022, HR 0.284 (0.096-0.837)].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation &amp; conclusions:<\/jats:title>\n                    <jats:p>The study adds to the growing literature that generic imatinib is effective and can be safely discontinued in CML-CP patients who are in deep molecular remission.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmr.ijmr_1090_21","type":"journal-article","created":{"date-parts":[[2023,2,26]],"date-time":"2023-02-26T23:20:44Z","timestamp":1677453644000},"page":"87-91","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Feasibility of treatment-free remission with generic imatinib"],"prefix":"10.25259","volume":"157","author":[{"given":"Deepak","family":"Goni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arihant","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charanpreet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Jindal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Nampoothiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Jandial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepesh","family":"Lad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alka","family":"Khadwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shano","family":"Naseem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Varma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","reference":[{"key":"R1-13-20241212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12288-019-01074-0","article-title":"CML in India: Are we there yet?","volume":"35","author":"Yanamandra","year":"2019","journal-title":"Indian J Hematol Blood Transfus"},{"key":"R2-13-20241212","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"R3-13-20241212","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"R5-13-20241212","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1007\/s00277-015-2319-x","article-title":"Changing the cost of care for chronic myeloid leukemia: The availability of generic imatinib in the USA and the EU","volume":"94","author":"Conti","year":"2015","journal-title":"Ann Hematol"},{"key":"R6-13-20241212","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JOP.2016.019737","article-title":"Journey of generic imatinib: A case study in oncology drug pricing","volume":"13","author":"Chen","year":"2017","journal-title":"J Oncol Pract"},{"key":"R7-13-20241212","doi-asserted-by":"crossref","first-page":"e330","DOI":"10.3324\/haematol.2019.222000","article-title":"The tolerability issue of generic imatinib in patients with chronic myeloid leukemia (Comment on Adi J Klil-Drori et al., Haematologica 2019;104(7): e293)","volume":"104","author":"Eskazan","year":"2019","journal-title":"Haematologica"},{"key":"R8-13-20241212","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3109\/10428194.2014.893302","article-title":"Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: A case series on an escalating issue impacting patient safety","volume":"55","author":"Saavedra","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"R9-13-20241212","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.3109\/10428194.2014.904508","article-title":"Prospective single-center study of chronic myeloid leukemia in chronic phase: Switching from branded imatinib to a copy drug and back","volume":"55","author":"Alwan","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"R10-13-20241212","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.3109\/10428194.2014.921299","article-title":"Generic imatinib: The real-deal or just a deal?","volume":"55","author":"Mathews","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"R11-13-20241212","first-page":"333","article-title":"Realized and projected cost-savings from the introduction of generic imatinib through formulary management in patients with chronic myelogenous leukemia","volume":"12","author":"Campbell","year":"2019","journal-title":"Am Health Drug Benefits"},{"key":"R12-13-20241212","first-page":"1","article-title":"Variation in adherence measures to imatinib therapy","volume":"4","author":"Yanamandra","year":"2018","journal-title":"J Glob Oncol"},{"key":"R13-13-20241212","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J Clin Oncol"},{"key":"R14-13-20241212","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00277-012-1468-4","article-title":"Comparative study of BCR-ABL1 quantification: Xpert assay, a feasible solution to standardization concerns","volume":"91","author":"L\u00f3pez-Jorge","year":"2012","journal-title":"Ann Hematol"},{"key":"R15-13-20241212","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/j.clml.2019.05.006","article-title":"Generic imatinib in chronic myeloid leukemia treatment: Long-term follow-up","volume":"19","author":"\u0106ojba\u0161i\u0107","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R16-13-20241212","doi-asserted-by":"crossref","first-page":"6559","DOI":"10.1002\/cam4.2545","article-title":"Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States","volume":"8","author":"Abou","year":"2019","journal-title":"Cancer Med"},{"key":"R17-13-20241212","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.clml.2017.05.006","article-title":"Generic imatinib in chronic myeloid leukemia: Survival of the cheapest","volume":"17","author":"Danthala","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R18-13-20241212","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/1078155214522143","article-title":"Clinical efficacy of generic imatinib","volume":"21","author":"de Lemos","year":"2015","journal-title":"J Oncol Pharm Pract"},{"key":"R19-13-20241212","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.3324\/haematol.2018.211235","article-title":"Persistence with generic imatinib for chronic myeloid leukemia: A matched cohort study","volume":"104","author":"Klil-Drori","year":"2019","journal-title":"Haematologica"},{"key":"R20-13-20241212","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"key":"R21-13-20241212","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"Sau\u00dfele","year":"2016","journal-title":"Leukemia"},{"key":"R22-13-20241212","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1182\/blood-2019-126002","article-title":"Patient-reported outcome results from the U.S. life after stopping TKIs (LAST) study in patients with chronic myeloid leukemia","volume":"134","author":"Flynn","year":"2019","journal-title":"Blood"},{"key":"R23-13-20241212","doi-asserted-by":"crossref","first-page":"7054","DOI":"10.1200\/JCO.2016.34.15_suppl.7054","article-title":"Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with second-line nilotinib (NIL): First results from the ENESTop study","volume":"34","author":"Hughes","year":"2016","journal-title":"J Clin Oncol"},{"key":"R24-13-20241212","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","article-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: The KID study","volume":"101","author":"Lee","year":"2016","journal-title":"Haematologica"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/ijmr.ijmr_1090_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T19:06:09Z","timestamp":1751483169000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmr.org.in\/feasibility-of-treatment-free-remission-with-generic-imatinib-results-of-generic-imatinib-free-trial-in-chronic-myeloid-leukaemia-chronic-phase-study\/"}},"subtitle":["Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study"],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmr.ijmr_1090_21","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]}}}